Biography

About Nic

Nic Gwatkin is a seasoned senior global and regional leader with extensive experience in market access and operational strategy across the EU, US, Japan, and China. He has worked in both large-scale and mid-sized pharmaceutical companies and has successfully founded three consulting firms specialising in market access and early commercialisation.

Nic has guided pharmaceutical development from phase 2 onwards and has been involved in the launch of 14 market-leading medicines across therapeutic areas including cardiovascular, haematology, ophthalmology, CNS, CG&T, and infectious diseases.

He is also deeply committed to talent development, having built teams recognised for leadership in diversity, empowerment, and creating environments where individuals thrive professionally.

Nic brings a wealth of global knowledge and experience to the Acumetis team.

Back to leadership team
Authored Posts

Published works and authored insights

June 24, 2026
Why Most Favored Nation pricing is becoming a political imperative
Explore how Most Favored Nation (MFN) pricing could impact pharmaceutical pricing, reimbursement, market access, and evidence strategies for life sciences organizations.
Reflection of person walking behind textured glass
April 6, 2026
How most favored nation policy is reshaping pharmaceutical pricing and market access
Discover how Most Favored Nation (MFN) policy impacts U.S. drug pricing and market access, from CMS enforcement to launch planning. Get the whitepaper now.
Window reflection to skyscrapers with man inside window
April 3, 2026
Most favored nation (MFN) exposure assessment
Implementation of a Most Favored Nation policy creates a great deal of uncertainty. We built this tool to help understand the impact for your business.